|
G |
Bcl2l11 |
Bcl2-like 11 |
increases expression |
ISO |
AZD 6244 results in increased expression of BCL2L11 protein |
CTD |
PMID:22729845 |
|
NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068
|
|
G |
Camp |
cathelicidin antimicrobial peptide |
multiple interactions |
ISO |
AZD 6244 promotes the reaction [Calcitriol promotes the reaction [resveratrol results in increased expression of CAMP mRNA]]; AZD 6244 promotes the reaction [resveratrol promotes the reaction [Calcitriol results in increased expression of CAMP mRNA]] |
CTD |
PMID:24039193 |
|
NCBI chr 8:109,841,729...109,843,543
Ensembl chr 8:109,841,729...109,843,543
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases cleavage |
ISO |
AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP3 protein]] AZD 6244 results in increased cleavage of CASP3 protein Doxorubicin promotes the reaction [AZD 6244 results in increased cleavage of CASP3 protein] |
CTD |
PMID:17876044 PMID:27222248 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp7 |
caspase 7 |
increases cleavage multiple interactions |
ISO |
AZD 6244 results in increased cleavage of CASP7 protein Doxorubicin promotes the reaction [AZD 6244 results in increased cleavage of CASP7 protein] |
CTD |
PMID:17876044 |
|
NCBI chr 1:255,437,195...255,476,737
Ensembl chr 1:255,437,172...255,476,729
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
ISO |
AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP8 protein]] |
CTD |
PMID:27222248 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Ccnb1 |
cyclin B1 |
decreases expression multiple interactions |
ISO |
AZD 6244 results in decreased expression of CCNB1 protein Doxorubicin promotes the reaction [AZD 6244 results in decreased expression of CCNB1 protein] |
CTD |
PMID:17876044 |
|
NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions |
ISO |
AZD 6244 results in decreased expression of and results in decreased phosphorylation of CCND1 protein; Doxorubicin promotes the reaction [AZD 6244 results in decreased expression of and results in decreased phosphorylation of CCND1 protein] |
CTD |
PMID:17876044 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
multiple interactions decreases expression |
ISO |
Doxorubicin promotes the reaction [AZD 6244 results in decreased expression of CDK2 protein] |
CTD |
PMID:17876044 |
|
NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403
|
|
G |
Cdk4 |
cyclin-dependent kinase 4 |
decreases expression multiple interactions |
ISO |
AZD 6244 results in decreased expression of CDK4 protein Doxorubicin promotes the reaction [AZD 6244 results in decreased expression of CDK4 protein] |
CTD |
PMID:17876044 |
|
NCBI chr 7:62,885,647...62,889,562
Ensembl chr 7:62,883,105...62,942,403
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions |
ISO |
AZD 6244 promotes the reaction [decitabine results in increased expression of CDKN1A] |
CTD |
PMID:19422044 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Chd4 |
chromodomain helicase DNA binding protein 4 |
multiple interactions |
ISO |
AZD 6244 inhibits the reaction [Harmine results in increased phosphorylation of CHD4 protein] |
CTD |
PMID:27805061 |
|
NCBI chr 4:157,898,503...157,931,632
Ensembl chr 4:157,899,391...157,931,541
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
decreases phosphorylation |
ISO |
AZD 6244 results in decreased phosphorylation of CREB1 protein |
CTD |
PMID:31790661 |
|
NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Eif4ebp1 |
eukaryotic translation initiation factor 4E binding protein 1 |
multiple interactions |
ISO |
[Ku 0063794 co-treated with AZD 6244] results in decreased phosphorylation of EIF4EBP1 protein |
CTD |
PMID:22415236 |
|
NCBI chr16:64,792,595...64,805,984
Ensembl chr16:64,790,226...64,805,984
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
decreases phosphorylation |
ISO |
AZD 6244 results in decreased phosphorylation of FOS protein |
CTD |
PMID:31790661 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Jak2 |
Janus kinase 2 |
increases phosphorylation |
ISO |
selumetinib increases phosphorylation of JAK2 protein in colonic epithelium |
RGD |
PMID:30706361 |
RGD:127285668 |
NCBI chr 1:226,995,334...227,054,381
Ensembl chr 1:226,995,334...227,054,189
|
|
G |
Kras |
KRAS proto-oncogene, GTPase |
multiple interactions |
ISO |
AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP3 protein]]; AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP8 protein]]; AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of PARP1 protein]]; AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of TNFRSF10B protein]; AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased phosphorylation of MAPK1 protein]; AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased phosphorylation of MAPK3 protein]; AZD 6244 inhibits the reaction [KRAS protein mutant form affects the susceptibility to vemurafenib] |
CTD |
PMID:27222248 |
|
NCBI chr 4:178,185,418...178,218,484
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions decreases phosphorylation |
ISO |
AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased phosphorylation of MAPK1 protein] AZD 6244 results in decreased phosphorylation of MAPK1 protein AZD 6244 results in decreased phosphorylation of and results in decreased activity of MAPK1 protein; Doxorubicin promotes the reaction [AZD 6244 results in decreased phosphorylation of and results in decreased activity of MAPK1 protein] |
CTD |
PMID:17876044 PMID:22415236 PMID:27222248 PMID:31790661 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions decreases phosphorylation |
ISO |
AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased phosphorylation of MAPK3 protein] AZD 6244 results in decreased phosphorylation of MAPK3 protein AZD 6244 results in decreased phosphorylation of and results in decreased activity of MAPK3 protein; Doxorubicin promotes the reaction [AZD 6244 results in decreased phosphorylation of and results in decreased activity of MAPK3 protein] |
CTD |
PMID:17876044 PMID:22415236 PMID:27222248 PMID:31790661 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mmp1 |
matrix metallopeptidase 1 |
decreases activity |
ISO |
AZD 6244 results in decreased activity of MMP1 protein |
CTD |
PMID:31790661 |
|
NCBI chr 8:4,658,588...4,679,099
Ensembl chr 8:4,658,588...4,679,097
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
decreases activity |
ISO |
AZD 6244 results in decreased activity of MMP2 protein |
CTD |
PMID:31790661 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
decreases activity |
ISO |
AZD 6244 results in decreased activity of MMP9 protein |
CTD |
PMID:31790661 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
multiple interactions decreases expression |
ISO |
Doxorubicin promotes the reaction [AZD 6244 results in decreased expression of MYC protein] |
CTD |
PMID:17876044 |
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases cleavage multiple interactions |
ISO |
AZD 6244 results in increased cleavage of PARP1 protein AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of PARP1 protein]] Doxorubicin promotes the reaction [AZD 6244 results in increased cleavage of PARP1 protein] |
CTD |
PMID:17876044 PMID:27222248 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Rps6ka1 |
ribosomal protein S6 kinase A1 |
multiple interactions decreases phosphorylation |
ISO |
Doxorubicin promotes the reaction [AZD 6244 results in decreased phosphorylation of RPS6KA1 protein] |
CTD |
PMID:17876044 |
|
NCBI chr 5:146,079,018...146,118,272
Ensembl chr 5:146,079,021...146,118,272
|
|
G |
Socs3 |
suppressor of cytokine signaling 3 |
multiple interactions |
ISO |
AZD 6244 inhibits the reaction [flavone results in increased expression of SOCS3 mRNA]; AZD 6244 inhibits the reaction [flavone results in increased expression of SOCS3 protein] |
CTD |
PMID:23782265 |
|
NCBI chr10:103,193,909...103,197,322
Ensembl chr10:103,193,537...103,197,787
|
|
G |
Ucp1 |
uncoupling protein 1 |
multiple interactions |
ISO |
AZD 6244 inhibits the reaction [Harmine results in increased expression of UCP1 mRNA] |
CTD |
PMID:27805061 |
|
NCBI chr19:24,808,782...24,816,853
Ensembl chr19:24,808,783...24,816,852
|
|